<DOC>
	<DOC>NCT01549847</DOC>
	<brief_summary>This protocol aims to assess of L-carnitine and piracetam to relieve weakness, muscle fatigue and muscle pain in patients with Postpoliomyelitis Syndrome.</brief_summary>
	<brief_title>A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Postpoliomyelitis Syndrome</mesh_term>
	<mesh_term>Muscle Weakness</mesh_term>
	<criteria>Patients with Postpoliomyelitis Syndrome diagnosis confirmed over a year; Electromyography test compatible with poliomyelitis; Preserved ability to swallow medication; Oral communication ability preserved; Preserved ability to perform pedaling test in at least one lower limb affected by Postpoliomyelitis Syndrome; Ability to understand information about the study and to document the decision about participating in the trial by signing the Informed Consent Form. History of intolerance to Lcarnitine or piracetam; Treatment with Lcarnitine during the past 3 months; Treatment with piracetam or any other nootropics pyrrolidone derivatives, during the past three months; Anemia (hemoglobin reference range men 13 to 17 g/dL and women 12 to 15 g/dL); High level of glycated hemoglobin (&gt; 7.0%); Electrolyte imbalance (hypokalaemia reference potassium concentration range: 3.5 to 5.6 mmol / L); Renal failure (creatinine reference range: 0.70 to 1.50 mg/dL); Urinary tract infection; Thyroid dysfunction (reference range: free T4: 0.54 to 0.67 mg/dL and TSH reference range: 0.5 to 5.5 Î¼UI/mL) or usual treatment with thyroid hormone supplementation; Cardiomyopathy; Uncontrolled hypertension; Known or suspected autoimmune disease; Confirmed pregnancy, or plans to get pregnant during the trial; Depression or bipolar affective disorders with moderate to severe episodes within the last twelve months; Insulindependent diabetes mellitus; Treatment with anticoagulant drugs over two weeks (including nonsteroidal antiinflammatory drugs (NSAIDs), warfarin, phenprocoumon, heparin); Usual cocaine or alcohol use; Any other condition judged by the investigator as a possibility to interfere on the participant's decision to be part of the study or to accomplish investigation procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Postpoliomyelitis Syndrome</keyword>
	<keyword>Piracetam</keyword>
	<keyword>L-Carnitine</keyword>
</DOC>